Robert Kerrey
Voorzitter bij Monolith Materials, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Robert J. Hanson | M | - |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | 12 jaar |
Sandy Mahatme | M | 59 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | 4 jaar |
Rahul Singhvi | M | 59 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | 4 jaar |
Peter J. Hébert | M | 46 |
Auris Health, Inc.
Auris Health, Inc. Medical SpecialtiesHealth Technology Auris Health, Inc. develops robotics technology for medical applications. The company was founded by Frederic H. Moll, Hariharan Sundram and Christopher J. P. Velis and is headquartered in Redwood City, CA. | - |
Pete Johnson | M | - |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | 12 jaar |
Elliott Broidy | M | - |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
Bill Brady | M | 62 |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | 12 jaar |
Sue Desmond-Hellmann | M | 66 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Jay Smith | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 jaar |
Patrick Hugh Conway | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 jaar |
Michelle A. Baron | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 12 jaar |
Ajay Royan | M | 45 |
Auris Health, Inc.
Auris Health, Inc. Medical SpecialtiesHealth Technology Auris Health, Inc. develops robotics technology for medical applications. The company was founded by Frederic H. Moll, Hariharan Sundram and Christopher J. P. Velis and is headquartered in Redwood City, CA. | - |
Mitchell Daniels | M | 48 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Nancy Thornberry | F | 67 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 jaar |
Sunita Zalani | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 10 jaar |
David P. Fridovich | M | - |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
Drew Oetting | M | - |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Reginald D. Hyde | M | - |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
Edward M. Reeder | M | - |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
Lex Phillips | M | - |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
Brett Smith | M | - |
Vortex Control Technologies LLC
Vortex Control Technologies LLC Packaged SoftwareTechnology Services Vortex Control Technologies LLC develops technology based products for aircraft control and safety. Its products include finlets and eaglets. The company is headquartered in Kennesaw, GA. | - |
Scott J. Horowitz | M | - |
Vortex Control Technologies LLC
Vortex Control Technologies LLC Packaged SoftwareTechnology Services Vortex Control Technologies LLC develops technology based products for aircraft control and safety. Its products include finlets and eaglets. The company is headquartered in Kennesaw, GA. | - |
Darren Farber | M | - |
Vortex Control Technologies LLC
Vortex Control Technologies LLC Packaged SoftwareTechnology Services Vortex Control Technologies LLC develops technology based products for aircraft control and safety. Its products include finlets and eaglets. The company is headquartered in Kennesaw, GA. | - |
Denice Torres | F | 64 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | 4 jaar |
Jeff van Steenbergen | M | - |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
Matthew Strongin | M | - |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | 8 jaar |
Peter David Smith | M | - |
Vortex Control Technologies LLC
Vortex Control Technologies LLC Packaged SoftwareTechnology Services Vortex Control Technologies LLC develops technology based products for aircraft control and safety. Its products include finlets and eaglets. The company is headquartered in Kennesaw, GA. | - |
David T. Dreier | M | 71 |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
John K. Rowan | M | 45 |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
Richard A. Drucker | M | - |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
James M. Simon | M | 76 |
Threat Deterrence Capital LLC
Threat Deterrence Capital LLC Miscellaneous Commercial ServicesCommercial Services Threat Deterrence Capital LLC operates as a holding company with interests in providing operational support, consulting, training, and engineering solutions. The company was founded on August 11, 2015 and is headquartered in Arlington, VA. | - |
Bryan Roberts | M | 57 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | - |
Douglas E. Patterson | M | 43 |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
Gino Santini | M | 67 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 jaar |
Kaye Foster-Cheek | F | 64 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Patrick Yang | M | 75 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Robert Nelsen | M | 60 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Jay Skyler | M | 77 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 jaar |
Joseph Kerrey | M | 80 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | - |
Thomas R. Alessi | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 27 jaar |
Dan Bradford | M | - |
Auris Health, Inc.
Auris Health, Inc. Medical SpecialtiesHealth Technology Auris Health, Inc. develops robotics technology for medical applications. The company was founded by Frederic H. Moll, Hariharan Sundram and Christopher J. P. Velis and is headquartered in Redwood City, CA. | 9 jaar |
Christopher Darby | M | 64 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | 4 jaar |
Stephen S. Trevor | M | 60 |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
George Barrett | M | 69 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | 4 jaar |
David J. Franklin | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 18 jaar |
Gil Morgan | M | - |
Vortex Control Technologies LLC
Vortex Control Technologies LLC Packaged SoftwareTechnology Services Vortex Control Technologies LLC develops technology based products for aircraft control and safety. Its products include finlets and eaglets. The company is headquartered in Kennesaw, GA. | - |
Scott Gottlieb | M | 51 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Steven Packebush | M | 59 |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
Dick Ford | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 18 jaar |
Frances Arnold | M | 67 |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | 4 jaar |
James Micali | M | 76 |
Monolith Materials, Inc.
Monolith Materials, Inc. Chemicals: SpecialtyProcess Industries Monolith Materials, Inc. operates as a carbon black manufacturing company. The firm converts natural gas to carbon black. It produces hydrogen tail-gas, supplied to the power generation and industrial gas markets. The company was founded by Peter L. Johnson, Robert Hanson, and William J. Brady Jr. in 2012 and is headquartered in Lincoln, NE. | - |
Olivia Zetter | F | - |
National Resilience, Inc.
National Resilience, Inc. Miscellaneous Commercial ServicesCommercial Services National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 jaar |
Raymond T. Keane | M | 65 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 jaar |
David Spellman | M | 48 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 jaar |
James Rosenthal | M | 70 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 3 jaar |
Thane Wettig | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | - |
Erin Colgan | F | 43 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 jaar |
Jonathan Anderman | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 59 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Robert Kerrey
- Persoonlijk netwerk